|
|
U.S. Colorectal Cancer Markets - Patient OutlookPublished by: Frost & Sullivan Published: Dec. 15, 2006 - 36 Pages Table of Contents
List of Figures Chapter 2
Chapter 3
AbstractResearch OverviewThe Frost & Sullivan research service titled U.S. Colorectal Cancer Markets: Patient Outlook is an update to Frost & Sullivan’s coverage of colorectal cancer. In this research service, Frost & Sullivan's expert analysts examine the patient population for colorectal cancer, 2003-2013. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this analysis:
Colorectal Cancer: Third Leading Cancer in the United States According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer in the United States in both men and women, and leads to the death of more than 55,000 people every year. Treatment is complex, with new product advances in both cytotoxic and targeted therapy drugs changing the landscape of options and pathways utilized by physicians to fight the disease. Like all cancer patients, those affected by colorectal cancer are divided according to factors such as disease progression and line of therapy. Proper understanding of the potential scope of these relative patient groups is important to judge the appropriate market size available for oncology products targeting colorectal cancer. With respect to therapies, adjuvant therapy is typically reserved until patients reach stage III of disease progression. Rectal cancer patients typically receive surgery, radiation therapy, and chemotherapy, while colon cancer patients just receive chemotherapy and surgery. "The percentage of patients receiving chemotherapy is increasing for both rectal and colon cancer patients and this trend combined with an aging patient population is expected to lead to the growth of the adjuvant therapy patient population," notes the analyst of this research service. "It is anticipated that by 2013, approximately 93 percent of stage III rectal cancer patients and 85 percent of stage III colon cancer patients will receive chemotherapy." Increasing Percentage of Stage IV Patients Accepting Pharmaceutical Treatment Stage IV colon and rectal cancers are normally treated with multiple modalities such as surgery, radiation, and pharmaceuticals or any combination of the three. Patient preference of the type of treatment is often followed due to the low survival rate of this end-stage disease. The five-year survival rate is a low 9.8 percent for patients diagnosed with stage IV cancer, and as a result, some patients do not wish to undergo intensive therapy. The projection through 2013 shows an increasing percentage of patients willing to accept treatment through pharmaceuticals. Going by the base year trends, approximately 74 percent of stage IV rectal cancer patients and 53 percent of stage IV colon cancer patients are estimated to take pharmaceuticals as part of their treatment in 2013. "Through 2013, population factors are expected to contribute to positive growth in the population for colorectal cancer, despite the fact that the incidence of colon and rectal cancers are declining slightly," says the analyst. "New treatments are expected to give Stage-IV patients new options in the second/third line of treatment, thus contributing to positive growth for those lines." Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||